(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 35.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Ascendis Pharma A's revenue in 2025 is $751,801,162.On average, 17 Wall Street analysts forecast ASND's revenue for 2025 to be $45,541,343,519, with the lowest ASND revenue forecast at $39,877,544,458, and the highest ASND revenue forecast at $49,846,930,573. On average, 17 Wall Street analysts forecast ASND's revenue for 2026 to be $81,932,627,196, with the lowest ASND revenue forecast at $62,197,922,808, and the highest ASND revenue forecast at $102,522,705,768.
In 2027, ASND is forecast to generate $114,681,238,812 in revenue, with the lowest revenue forecast at $80,710,664,076 and the highest revenue forecast at $150,545,856,384.